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Abstract
Purpose Patients suffering from gastrointestinal mucositis of-
ten receive parenteral nutrition as nutritional support.
However, the absence of enteral nutrition might not be bene-
ficial for the intestine. We aimed to determine the feasibility of
minimal enteral feeding (MEF) administration in a methotrex-
ate (MTX)-induced mucositis rat model and thereby deter-
mine the effect of MEF on recovery.
Methods Male Wistar rats were attached to swivel systems
from day 1 to 5 after 45 mg/kg MTX IV injection. The
MTX group continued ad libitum feeding, and the MTX+
MEF group continued ad libitum feeding and received from
day 1 to 5 continuously MEF. MEF consisted of 20 % of their
normal caloric intake. We measured body weight, intake, and
plasma citrulline. At day 10, the rats were terminated and
villus and crypt length were measured.
Results The administration of MEF caused no increased se-
verity of mucositis phenotype, with comparable caloric intake,
body weight, and plasma citrulline during mucositis. The re-
covery of plasma citrulline levels was not different between
both groups. At day 7 and 8, the MTX+MEF group gained
significantly more weight (p<0.05 and p<0.01, respectively),
and at day 8 and 9 the total caloric intake was significantly
increased (p<0.01 and p<0.05, respectively) compared to the
MTX group. At day 10, the rats from the MTX+MEF group
showed a significant increase in jejunal villus length com-
pared to the MTX group (p<0.05).
Conclusions This is the first study in which the feasibility of
MEF administration during chemotherapy-induced mucositis
was determined. This study indicates that MEF administration
is feasible during mucositis and suggests that MEF accelerates
recovery after MTX-induced mucositis.
Keywords Gastrointestinal mucositis . Minimal enteral
feeding . Nutrition . Chemotherapy .Methotrexate .
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Introduction
Gastrointestinal mucositis, further referred to as mucositis, is a
severe side effect of chemotherapy and radiotherapy [1].
Mucositis is a common clinical problem with an estimated
incidence of 40–100 % of patients with chemotherapy [2].
The incidence is particularly high in children with acute my-
eloid leukemia, B-non-Hodgkin lymphoma, and after autolo-
gous and allogeneic stem cell transplantation, due to the high
dosage of chemotherapy. Mucositis is a mechanism of differ-
ent biological stages resulting in villus atrophy, ulceration, and
loss of barrier function, ending with spontaneous healing
[1–3]. Patients suffer from nausea, vomiting, diarrhea, pain,
and weight loss, and are at an increased risk of sepsis or bac-
teremia [1, 2, 4]. The consequences of mucositis limit the
ability to tolerate chemotherapy and therefore cause a reduc-
tion of doses of chemotherapy or cause a delay of the next
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chemotherapy cycle, which eventually affects the patient sur-
vival [2].
An optimal feeding strategy during mucositis might
improve the nutritional state and thereby increase sur-
vival, but until now there is no rational feeding strategy.
In previous animal studies, we have shown that amino
acids and glucose were only absorbed if continuously
enterally administered [5–7]. However, fatty acids and
lactose were not digested and absorbed even if contin-
uously enterally administered [5, 8]. We concluded that
administration of total enteral tube feeding is not feasi-
ble in the rat, and for the rat the parenteral feeding
regimen is superior to maintain body weight, compared
to the enteral regimen [9]. However, total parenteral
nutrition has disadvantages. In animal models of other
intestinal diseases, it has been shown that total paren-
teral nutrition induces apoptosis, villus atrophy, and mu-
cosal permeability, probably due to the lack of enteral
nutrition [10–13]. This might be even more disadvanta-
geous in patients already experiencing mucositis.
The disadvantages of the lack of trophic effects might be
overcome by minimal enteral feeding (MEF), a small amount
of elementary nutrition administered as continuous tube feed-
ing. MEF has been shown to have a positive effect on intesti-
nal growth, enterocyte function, and maintenance of barrier
function in animal models concerning other intestinal dis-
eases, and has often been used in the premature infant
[14–17]. However, there are no data on the use ofMEF during
mucositis.
MEF could be an intervention to accelerate the re-
generation of the damaged intestinal mucosa after che-
motherapy and consequently speed up recovery to over-
come the lack of trophic effects during treatment with
total parental nutrition. Therefore, we chose to deter-
mine the feasibility of MEF administration during mu-
cositis in a methotrexate (MTX)-induced intestinal mu-




Male Wistar outbred rats (4 weeks old, 85–95 g) were
obtained from Charles River (Sulzfeld, Germany). They
were housed in individual Plexiglas cages under con-
trolled temperature and humidity, and a 12–12 h light–
dark cycle (7.00AM–7.00PM). AIN93G diet [5, 18] and
water were available ad libitum. The study protocol was
approved by the Ethics committee for Animal experi-
ments, Faculty of Medical Sciences, University of
Groningen, The Netherlands.
Materials
Methotrexate was obtained from Pharmachemie Holding B.V.
(Haarlem, the Netherlands). Purified diet, AIN93G, was ob-
tained from Research Diet Services (Wijk bij Duurstede, the
Netherlands). Tube feeding Neocate® Advance was purchased
from Nutricia (Zoetermeer, the Netherlands).
Experimental methods
Rats had surgery 1 week after arrival at the age of 5–6 weeks.
They received a permanent catheter in the duodenum which
was subcutaneously tunneled to the head, where attachment to
the swivel system was possible, as done before [9]. All rats
were allowed to recover 1 week. At day 0, at an age of
6–7 weeks, the rats (199–221 g) received MTX 45 mg/kg
(n=14) or NaCl 0.9 % (n=2) intravenously (iv) in the dorsal
penile vein under general anesthesia. In a pilot experiment, the
previous validated dose of 60 mg/kg MTX induced too much
toxicity in the rats in this experimental design (data not
shown). Therefore, the dose of MTX was lowered from 60
to 45 mg/kg. After the MTX/NaCl injection, all rats were
attached to swivels in a cage with filter top, a swivel joint
and counterbalance system from day 1 till day 5, as done
before [9, 19]. From day 5 till day 10, all rats were in their
regular Plexiglas cages unattached from the swivels. Daily
food intake and body weight were measured, and diarrhea,
pica (= ingestion of non-food substances as sign of emesis
[20, 21]), and illness (bad fur, red nose, or decreased activity)
were scored as yes/no. Every 2 days, the severity of mucositis
was objectified by measuring plasma citrulline levels in blood
samples from the tail tip (70 μl). Plasma citrulline represents
functional enterocyte mass and is a marker of mucositis
[22–26]. At day 10, all rats were euthanized under general
anesthesia by obtaining a large blood sample through vena
cava inferior puncture, followed by cervical dislocation.
Blood samples were centrifuged for 10 min at 2000×g and
collected plasma was stored at −20 °C until further analysis.
The abdomen was opened and the small intestine excised, and
flushed with PBS. Smaller parts for jejunal histology (1 cm)
were fixed in formalin, dehydrated, and embedded in paraffin
according to standard procedures for histology.
Feeding strategies
All three groups continued AIN93G ad libitum during
the complete experiment because a forced food restric-
tion of 80 % for 4 days in the MTX+MEF group was
regarded to be not ethical. Controls (n=2) received
NaCl 0.9 % iv to show the normal intake and growth
when attached to a swivel system. Only two control rats
were used since we have used this model many times,
and control rats have performed similarly over all
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studies [5–9]. All other rats were randomly divided into
two groups. The MTX group (n=7) received MTX
45 mg/kg iv. The MTX+MEF group (n=7) received
MTX 45 mg/kg iv and received from day 1 to 5 forced
continuous minimal enteral tube feeding containing
20 % of the normal total caloric intake. This amount
of tube feeding was based on the use of MEF in animal
studies in other intestinal diseases [13, 15, 16]. From
our previous studies, we know that saline-treated control
rats eat about an average of 329 kcal/kg/day of AIN93G
[5, 9, 18]. The caloric intake was daily adapted to the
body weight, 66 kcal/kg/day, and the enteral tube feed-
ing was prepared twice daily. The enteral tube feeding
used in this study was Neocate® Advance, which is the
most elementary diet available in clinical practice at the
moment. In Table 1, the feeding strategies with distri-
bution of calories via enteral tube are summarized, and
in Table 2 the energy distribution and composition of
both diets are summarized.
Analytical methods
Histology
Hematoxylin and eosin staining (H&E) was done on
3-μm-thick sections of formalin-fixed jejunal segments
to assess histology. Morphometric analysis was per-
formed as described previously [5, 27]. The H&E slides
were scanned using the Aperio Scanscope (Aperio
Technologies, Vista, CA, USA). Villus and crypt length
were measured manually in well-orientated sections (ten
measurements per rat) from digitized images that were
evaluated at ×10 magnification by using Aperio
Imagescope software (Aperio Technologies).
Plasma citrulline concentration
In 30 μl plasma (=70 μl blood) at room temperature, the
plasma citrulline concentration was measured by using auto-
mated ion exchange column chromatography, as described
before [5, 28, 29].
Statistical analysis
Statistical analysis was done by using SPSS version 22.0 for
Windows (SPSS Inc., Chicago, IL, USA). The values are
expressed as medians and ranges in text, or interquartile
ranges in figures. The two control rats were not included in
the statistical analysis. Data analysis between the MTX and
MTX+MEF group was performed by using a Mann-Whitney
U test. A p value <0.05 was considered statistically
significant.
Results
MEF in the mucositis rat model
We determined the feasibility of MEF administration during
mucositis and the effect of MEF on recovery. All rats tolerated
the MTX 45 mg/kg and tolerated the administration of MEF
during four consecutive days via attachment to the swivel
system. One rat from the MTX group had to be terminated
on day 9 due to too much weight loss and illness. One rat from
the MTX+MEF group died shortly after start of the tube feed-
ing, due to a problem with the duodenal catheter, and was
therefore excluded from analysis. All rats from both MTX
groups developed a mucositis phenotype, with decreased food
intake and less growth, as described below. Other features of
the mucositis phenotype were illness (bad fur, red nose, or
Table 1 Feeding strategies
Controls MTX group MTX+MEF group
NaCl 0.9 % (n=2) MTX (n=7) MTX (n=6–7)a
Feeding strategy Ad libitum Ad libitum MEF+ad libitum
Diet ad libitum (kcal) AIN93G (3.76 kcal/g) AIN93G (3.76 kcal/g) AIN93G (3.76 kcal/g)
Amount Ad libitum Ad libitum Ad libitum
Tube feeding – – 20 % of normal kcal intake=MEFb
Diet for tube feeding (kcal/kg) – – Neocate® Advance
(4000 kcal/kg)
250 g/l=1000 kcal/l
Amount – – 66 kcal in 66 ml/kg/day
Total amount Ad libitum Ad libitum 66 kcal/kg/day+ad libitum
MTX methotrexate, MEF minimal enteral feeding
a One rat died shortly after start of the tube feeding and was therefore excluded from analysis
b Average normal kcal intake known from previous experiments is about 329 kcal/kg/day [5, 9, 18]
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decreased activity), pica, and diarrhea, which did not differ
between both MTX groups (data not shown).
Intake
The food intake of both MTX groups decreased during the
days of mucositis, day 1–5. At day 3, the median AIN93G
food intake in grams in the MTX+MEF group was signifi-
cantly lower compared to the MTX group (3.5, 0–7, and 12,
3–13, respectively; p<0.05).
Figure 1a shows the total energy intake in calories, which is
a combination of the food intake and MEF. All rats from the
MTX+MEF group received daily 20 % of their calculated
normal caloric intake via tube feeding, during day 1 till
day 5. The total caloric intake was comparable in the MTX+
MEF group and MTX group during mucositis. However, dur-
ing the recovery phase, on day 8 and 9, theMTX+MEF group
had a significantly higher total caloric intake compared to the
MTX group (p<0.01 and p<0.05, respectively).
Body weight
Figure 1b shows the weight gain over time in grams per day.
Figure 1c shows the body weight from day 0 till day 10. At
day 0, before MTX injection, the body weight in all groups was
Table 2 Energy distribution and composition of diet
Neocate® Advance AIN93G [18]
Kcal 4000 kcal/kg 3760 kcal/kg
Energy distribution
Proteins 10 % 19 %
Carbohydrates 59 % 64 %
Fats 31 % 17 %
Composition of diets, per kg diet
Protein equivalent (g) 100 a
Free amino acids (g) 120 a
Casein (g) – 200
L-Cystine (g) – 3
Carbohydrate 585 g
Cornstarch (g) – 529.5
Glucose (g) 12 –
Maltose (g) 41 –
Maltotriose (g) 59 –
Sucrose (g) – 100
Lactose (g) – –
Polysaccharides (g) 473 50
Fat 140 g 70 g soybean oil
Saturated (g) 53 10.8
MCT (g) 47 –
Monounsaturated (g) 61 16.3
Polyunsaturated (g) 19 40.5
- Linoleic acid (g) 16 35.7
- Linolenic acid (g) 3 4.8
Minerals 35 g/kg mineral mix
Sodium (mg) 2400 1019
Potassium (mg) 4680 3600
Chloride (mg) 3680 1571
Calcium (mg) 2000 5000
Phosphorus (mg) 1560 1561
Magnesium (mg) 500 507
Iron (mg) 24.8 35
Zinc (mg) 20 38
Copper (mg) 2.4 6.0
Manganese (mg) 20 10
Molybdenum (mg) 0.14 0.15
Selenium (mg) 0.1 0.15
Chromium (mg) 0.05 1.0
Iodine (mg) 0.28 0.2
Silicon (mg) – 5.0
Nickel (mg) – 0.5
Boron (mg) – 0.5
Lithium (mg) – 0.1
Vanadium (mg) – 0.1
Fluoride (mg) – 1.0
Table 2 (continued)
Neocate® Advance AIN93G [18]
Vitamins 10 g/kg vitamin mix
Vitamin A 1480 μg RE 4000 IU
- Carotenoids – –
Vitamin D 32.4 μg 1000 IU
Vitamin E 23.2 mg α-TE 75 IU
Vitamin K (μg) 140 750
Thiamin (mg) 2.4 5
Riboflavin (mg) 3.2 6
Niacin 72 mg NE –
Pantothenic acid (mg) 10 15
Vitamin B6 (mg) 3.2 –
Folic acid (mg) 0.4 2
Vitamin B12 (μg) 2.8 25
Biotin (μg) 80 200
Vitamin C (mg) 132 –
Others
Carnitine (mg) 100 –
Choline (mg) 768 1000
Taurine (mg) 200 –
MCT medium chain triglycerides
a Exact amount of protein equivalent and exact amount of free amino
acids in casein are unavailable. Casein and L-cystine are the sole source
of protein in AIN93G diet
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comparable. For bothMTX groups, the body weight stabilized or
the rats lost weight during the first days of mucositis. In the
recovery phase (day 5–10), both MTX groups regained growth
and increased weight from day 5 after MTX. However, at day 7
and day 8, the weight gain of the MTX+MEF group was signif-
icantly higher compared to theMTX group (p<0.05 and p<0.01,
respectively). At day 10, the body weight of the MTX+MEF
group tended to be higher compared to theMTX group (p=0.08).
Plasma citrulline
Figure 2 shows the plasma citrulline levels from day 0 till
day 10. The plasma citrulline levels decreased to the lowest
level at day 4 in both the MTX group and MTX+MEF group.
The plasma citrulline level at day 10was not different between
the MTX and MTX+MEF group (p=0.15).
Histology
Figure 3 shows the villus length and crypt length at day 10 with a
histological example of bothMTX andMTX+MEF in Fig. 4. At
day 10, the rats from the MTX+MEF group showed a
significantly higher villus length in the jejunum compared to the
MTX group (p<0.05), a comparable length as controls (577 μm,
530–624). The crypt length in the jejunum was comparable in
both groups, a comparable length as controls (188μm, 179–198).
Discussion
This is the first study in which the feasibility of MEF admin-
istration during chemotherapy-induced mucositis was deter-
mined. Our data indicate that the administration of MEF dur-
ing mucositis is feasible, that MEF does not increase morbid-
ity due to mucositis, and even more, it suggests that MEF
accelerates recovery in a previously established MTX-
induced mucositis rat model.
First, we determined the feasibility of MEF administration
during MTX-induced mucositis. The effects of MTX on in-
duction of mucositis became apparent in the clinical parame-
ters during the first four days after MTX administration. The
body weight of the rats stabilized, as opposed to controls
which continued to grow, and the food intake decreased dur-
ing mucositis in both MTX groups. The development of
a b c
Fig. 1 Intake and body weight. Total intake (a), body weight gain per
day (b), and body weight over time (c) in methotrexate (MTX)-treated
rats. In MTX group, total intake consists of the AIN93G food intake. In
the MTX+minimal enteral feeding (MEF) group, total intake consists of
AIN93G food intake combined with MEF. MTX iv injection at day 0.
MEF was administered from day 1 to 5 in the MTX+MEF group. Data
represent medians and interquartile ranges (a–c). a, bMTX (n=7; n=6 at
day 9 because one rat had to be terminated at day 9), MTX+MEF (n=6).
*p<0.05 and **p<0.01 MTX versus MTX+MEF. cMTX (n=7; n=6 at
day 10 because one rat had to be terminated at day 9), MTX+MEF (n=6).
The dashed line shows the median of the controls
Fig. 2 Plasma citrulline. Citrulline (μmol/l) measured every 2 days. Data
represent medians and interquartile ranges. Methotrexate (MTX) iv
injection at day 0. Minimal enteral feeding (MEF) was administered
from day 1 to 5. MTX+MEF (n=6) and MTX (n=7; n=6 at day 10
because one rat had to be terminated at day 9). The dashed line shows
the median of the controls
a b
Fig. 3 Villus and crypt length. Jejunal villus length at day 10 (a). Jejunal
crypt length at day 10 (b). Data representmedians and interquartile ranges
(n=6–7). Measurements in one rat in the methotrexate (MTX) group
performed at day 9. *p<0.05 MTX+minimal enteral feeding (MEF)
versus MTX. ns not significant
Support Care Cancer (2016) 24:1357–1364 1361
mucositis was comparable with our previous studies, with the
lowest level of plasma citrulline (a marker of functional
enterocyte mass) at day 4 [5–9]. MEF caused no altered func-
tional enterocyte mass compared with MTX group.
Furthermore, the administration of MEF caused no increased
severity of mucositis phenotype, with comparable caloric in-
take and body weight during mucositis. Therefore, the results
show that it is feasible to administer MEF during four consec-
utive days in this MTX-induced mucositis rat model.
Further, after the feasibility of MEF administration during
mucositis, we determined the effect of MEF on the recovery
after mucositis. First, the clinical parameters showed a signif-
icant higher food intake and weight gain after mucositis.
Although the difference in body weight between both groups
at day 10 only tended to be higher, our results suggest a trend
for a faster recovery of body weight gain due toMEF. Second,
in the recovery phase, citrulline levels reached their normal
levels again, although there was no significant difference in
the citrulline levels between both groups. Finally, we deter-
mined the intestinal damage by histology at termination, with
the measurement of villus length and crypt length 10 days
after MTX. The crypts were completely recovered regardless
of MEF on day 10 and are comparable to the crypt length of
controls. This was as expected since we know from previous
studies that crypts regenerate rapidly and prior to the recovery
of villus atrophy, with even crypt hyperplasia shown at 96 h
after MTX injection [5, 30]. However, the villus length was
significantly longer in the MTX+MEF group, comparable to
controls in this study and to the villus length determined at
several time points in a previous study [30]. Therefore, this
indicates a faster recovery of villus atrophy. In conclusion, the
data suggest that MEF administration might accelerate recov-
ery after mucositis, with a faster recovery of villus atrophy in
combination with faster recovery of clinical parameters like
intake and body weight gain.
To our knowledge, this is the first study that determined the
feasibility and effect of MEF administration continuously dur-
ing mucositis. Therefore, we cannot compare our results di-
rectly to other performed experiments. However, our results
agree with studies performed in animal models of other intes-
tinal diseases, concluding that MEF stimulates the intestine
with an increase in jejunal villus length [14–16]. It should be
noted that we did not compare different percentages of MEF;
therefore, the optimal amount of MEF necessary for a faster
recovery after mucositis was not established in this study. The
percentage we used was comparable to the percentage tolerat-
ed in clinical practice and comparable to percentages in animal
studies of other intestinal diseases in which MEF has been
shown to be feasible and effective [15, 16].
In contrast to other studies, we did not administer parenter-
al nutrition in combination with MEF [14–16]. We chose for
this protocol since we wanted to determine the feasibility of
MEF administration reflected in parameters like body weight
and intake, which would be confounded by simultaneous par-
enteral nutrition.
Interestingly, administration of MEF reduced food intake
of the rats, although total caloric intake remained the similar.
The differences between both groups are the composition of
both diets and the timing of the intake. The MEF is a contin-
uous supplied elementary diet, and thus most of the nutrients
do not have to be digested before absorption. Moreover, the
normal food intake of the rats takes place in boluses, whereas
we know that this bolus feeding is not effectively absorbed
during mucositis [5–8]. Therefore, the continuous intestinal
stimulation with elementary nutrients is not only feasible dur-
ing mucositis but it may cause even a faster recovery, as
shown in a faster recovery of intake, body weight gain, and
villus length. Since the AIN93G diet probably also has trophic
effects on the gut, the cause of this faster recovery remains
unclear.
There are some limitations to this study. First, we did not
compare MEF only versus ad libitum intake because a forced
food restriction of 80 % for 4 days was regarded to be not
ethical. However, in our opinion this study design, MEF+ad
libitum versus ad libitum, was still sufficient to answer the
primary objective. Second, in patients the effect of chemother-
apy on the intestine probably happens less fast and the recov-
ery phase is longer [2]. Therefore, our model does not
Fig. 4 Histology of jejunum.
Hematoxylin and eosin (H&E)
staining showing morphology at
day 10. Bars represent 300 μm. a
Methotrexate (MTX) rat. b
MTX+minimal enteral feeding
(MEF) rat
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completely fit into clinical practice, although we do believe
that this does not make our results less likely to be useful in the
human setting. Third, the body weight in pediatric patients
logically does not increase as fast as in rats. However, we
chose these young rats to see the feasibility and effect of
MEF administration in the very short recovery phase.
Therefore, we speculate that the advantage of MEF adminis-
tration might be even more pronounced in patients due to the
longer recovery phase. Finally, we did not determine the in-
testinal function during and after mucositis. Therefore, we
cannot draw any conclusions about recovery of the intestinal
function.
In clinical practice, the optimal feeding strategy during mu-
cositis is unknown. Patients are often unable to tolerate enteral
nutrition and therefore often receive parenteral nutrition as
nutritional support. However, the absence of enteral nutrition
might not be beneficial for the intestine. In this study, we
showed that MEF administration is feasible during mucositis
and moreover our data suggest that MEF accelerates recovery.
Therefore, MEF might be a good option to overcome the
effects on the gut due to the lack of enteral nutrition.
Furthermore, we speculate that MEF might have a positive
effect on recovery, allowing the patient to either receive a
higher dose of chemotherapy or to start the next chemotherapy
course according to the protocol without any delay, which
eventually might influence the survival.
The results of our study warrant the much more technically
difficult study of TPN versus TPN+MEF and future studies in
humans on the use of MEF in patients with mucositis, to
determine the beneficial effects of the additive of MEF to
parenteral nutrition, and to understand the mechanism of
action.
In summary, this is the first study that determined the
feasibility of MEF administration during mucositis and
the effect of MEF on the recovery after mucositis. The
administration of MEF causes no increased severity of
the mucositis phenotype and is therefore feasible during
mucositis. Even more, in the MTX+MEF group, the
intake and body weight gain were significantly higher
in the recovery phase. Moreover, the villus length was
significantly longer 10 days after MTX. Therefore, our
data suggest that MEF speeds up the recovery after
mucositis in the rat. The effect of MEF may be even
more pronounced in patients due to a longer recovery
phase in comparison to the rat. If a patient receives
parenteral nutrition, MEF might be a good option to
overcome the lack of enteral nutrition.
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